Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 3/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5261981 | 0.90 | ESR1 (0.48) | KDM4ETP53TSHRPDGFRBPDGFRA | |
| SCHEMBL5257252 | 0.84 | PTPN1 (0.39) | HRH3 | |
| SCHEMBL5314011 | 0.83 | POLB (0.46) | KDM4ETP53TSHRMAPK14ESR1 | |
| SCHEMBL5260629 | 0.81 | ESR1 (0.47) | KDM4EPDGFRBPDGFRAESR1 | |
| SCHEMBL5257242 | 0.81 | PLA2G10 (0.45) | ESR1 | |
| SCHEMBL5309119 | 0.80 | MAP3K8 (0.49) | KDM4ETSHREPHX2 | |
| SCHEMBL5254962 | 0.78 | MAPT (0.46) | KDM4ETP53TSHR | |
| SCHEMBL5256604 | 0.76 | DYRK1A (0.47) | KDM4E | |
| SCHEMBL5310989 | 0.76 | PTPN1 (0.44) | KDM4ETSHRCNR2 | |
| SCHEMBL5314813 | 0.75 | CNR1 (0.46) | KDM4ETSHRCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1578424-A4 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A| QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2007-08-08 | — | — | EP | claimed |
| US-7135480-B2 | Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers | CYTOVIA, INC. (US) | 2006-11-14 | — | — | US | claimed |
| EP-1578424-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20050014759-A1 | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2005-01-20 | — | — | US | claimed |
| WO-2004055163-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO[1,2-A]QUINOLINES | CYTOVIA, INC. (US) | 2004-07-01 | — | — | WO | claimed |
| EP-1578424-A4 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A| QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | CYTOVIA INC (US) | 2007-08-08 | — | — | EP | disclosed |
| US-7135480-B2 | Anticarcinogenic agents; colon, lymphoma, lung, prostate and breast cancers | CYTOVIA, INC. (US) | 2006-11-14 | — | — | US | disclosed |
| EP-1578424-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO 1,2-A] QUINOLINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS | Cytovia, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| US-20050014759-A1 | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | CYTOVIA, INC. | 2005-01-20 | — | — | US | disclosed |
| WO-2004055163-A2 | SUBSTITUTED 1-BENZOYL-3-CYANO-PYRROLO[1,2-A]QUINOLINES | CYTOVIA, INC. (US) | 2004-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014759-A1 | Substituted 1-benzoyl-3-cyano-pyrrolo [1,2-a] quinolines and analogs as activators of caspases and inducers of apoptosis | CASP3, CASP7, CASP1 | KDM4E 570/4885TP53 53/4885TSHR 3936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.